LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.

We came across a bullish thesis on Eli Lilly and Company (LLY) on Business Model Mastery’s Substack. In this article, we will summarize the bulls’ thesis on LLY.

Furthermore, LLY stock has already absorbed some significant impact, having fallen over 20% from its 52-week high of over $970 to current levels below $750.

PFE stands above LLY thanks to its solid earnings outlook, and based on these valuation figures, we also feel that PFE is the superior value option right now.

Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly LLY revealed 63 unusual trades. Delving into the details, we found 42% of traders ...

Eli Lilly (NYSE:LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter half of 2024 and has been underperforming since. The latest executive ...

Porsche has revealed a new special edition, the 2025 911 Turbo 50 Years. Based on the 992.1 Turbo S, it's a throwback to the original 911 Turbo of 1974.

LLY stock has fared well so far this year, up around 20%. At its current levels of $920, LLY looks attractive but volatile - making it a tricky pick to buy.

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor letter. A copy of the investor letter can be downloaded here. U.S.

The Duramax diesel is a series of diesel engines manufactured by General Motors. Here's a breakdown of the generations over ...